예측 기간
시장 규모(기준 연도)
시장 규모(예측 연도)
연평균 성장률유럽 고함량 스크리닝 시장, 제품 유형(기기, 소모품, 소프트웨어, 서비스 및 액세서리), 응용 분야(1차 및 2차 스크리닝, 표적 식별 및 검증, 독성 연구, 화합물 프로파일링 및 기타 응용 분야), 기술(현미경, 유세포 분석 , 면역조직화학, 세포외 기질 기반 스캐폴드, ELISA, 웨스턴 블로팅 및 기타), 최종 사용자(제약 및 생명공학 회사, 계약 연구 기관, 실험실, 학계 및 정부 기관, 기타), 유통 채널(직접 입찰, 소매 판매) - 업계 동향 및 2030년까지의 예측.
유럽 고용량 스크리닝 시장 분석 및 통찰력
세포 기반 분석 및 약물 발견과 같은 연구 활동에서 HCS를 채택하는 것이 증가함에 따라 시장 수요가 증가했습니다. 약물 발견 및 관련 연구 프로그램에 대한 정부 이니셔티브와 자금 지원도 시장 성장에 기여합니다. 주요 시장 참여자는 이 중요한 기간 동안 다양한 서비스 출시 및 승인에 집중합니다. 또한, HCS 시스템을 사용한 영상 기술과 인공 지능 의 향상된 발전 도 HCS에 대한 수요 증가에 기여합니다.
시장은 시장 참여자 수의 증가와 첨단 기술 HCS 장비의 가용성으로 인해 예측 연도에 성장할 것으로 예상됩니다. 이와 함께 제조업체는 첨단, 새롭고 효율적인 HCS 시스템을 출시하기 위한 개발 활동에 참여하고 있습니다. 첨단 기술 분야의 개발 증가는 시장 성장을 더욱 촉진할 것으로 예상됩니다. 그러나 HCS 제품의 생산 및 상용화에 대한 엄격한 규정과 같은 어려움은 시장 성장을 제한할 것으로 예상됩니다.
Data Bridge Market Research에 따르면 유럽 고내용 스크리닝 시장 규모는 2030년까지 1,057,169.94만 달러에 도달할 것으로 예상되며, 2023~2030년 예측 기간 동안 연평균 성장률은 6.8%입니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2023년부터 2030년까지 |
|
기준 연도 |
2022 |
|
역사적 연도 |
2021 (2015-2020까지 사용자 정의 가능) |
|
양적 단위 |
수익 (USD 천) |
|
다루는 세그먼트 |
제품 유형(기기, 소모품, 소프트웨어, 서비스 및 액세서리), 응용 분야(1차 및 2차 스크리닝, 타겟 식별 및 검증, 독성 연구, 화합물 프로파일링 및 기타 응용 분야), 기술( 현미경 , 유세포 분석, 면역조직화학, 세포외 기질 기반 스캐폴드, ELISA, Western Blotting 및 기타), 최종 사용자(제약 및 생명공학 회사, 계약 연구 기관, 실험실, 학술 및 정부 기관, 기타), 유통 채널(직접 입찰, 소매 판매) |
|
적용 국가 |
독일, 프랑스, 영국, 이탈리아, 스페인, 러시아, 터키, 벨기에, 덴마크, 네덜란드, 스위스, 스웨덴, 폴란드, 노르웨이, 핀란드 및 기타 유럽 국가 |
|
시장 참여자 포함 |
BD, Merck KGaA, Corning Incorporated, Carl Zeiss AG, Sartorius AG, Zifo RnD Solutions, Axxam SpA, Molecular Devices, LLC. (Danaher Corporation의 자회사), Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Yokogawa Electric Corporation, Sysmex Corporation, Genedata AG, Miltenyi Biotec, Aligned Genetics, Inc. 등 |
유럽 고용량 스크리닝 시장 정의
고함량 스크리닝(HCS)은 고함량 분석(HCA)이라고도 하며, 약물 발견 및 시스템 생물학과 같은 대규모 응용 분야에 적합한 고처리량 형식으로 자동 이미징과 정량적 데이터 분석을 결합한 세포 생물학 접근 방식입니다.
이 시장은 대규모 세포 과정과 생물학적 현상을 연구하고 분석하기 위해 고급 이미징 및 분석 기술을 사용하는 데 중점을 둔 생명 과학 산업 분야를 말합니다. HCS는 형광 현미경, 자동 액체 취급 및 정교한 이미지 분석 소프트웨어와 같은 기술을 사용하여 세포 또는 유기체의 자동 이미징 및 정량 분석을 포함합니다.
유럽 고용량 스크리닝 시장 동향
이 섹션에서는 시장 동인, 이점, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.
운전사
- 고용량 스크리닝에 사용되는 이미징 기술의 발전
이미징 기술은 고함량 스크리닝(HCS)의 최전선에 있으며, 연구자들이 전례 없는 세부 사항과 정밀도로 세포 과정을 시각화하고 분석할 수 있도록 합니다. 고해상도 이미징 외에도 이미징 속도와 처리량이 크게 향상되었습니다. HCS는 종종 고처리량 형식으로 많은 수의 샘플을 분석하는 데 도움이 됩니다. 이미징 기술은 더 빠른 수집 시간을 제공하도록 발전하여 연구자들이 더 짧은 기간에 대용량 데이터 세트를 분석할 수 있도록 합니다. 회전 디스크 공초점 현미경 및 광시트 현미경과 같은 고속 이미징 기술은 이미지 품질을 손상시키지 않고도 빠른 이미지 수집을 가능하게 하여 효율적인 스크리닝 워크플로 및 데이터 분석을 용이하게 합니다.
수년에 걸쳐 영상 모달리티, 현미경 기술, 영상 분석 도구가 크게 발전하여 HCS의 환경이 변화하고 시장이 확대되었습니다.
기회
- 약물 발견 및 개발에서 인공 지능 및 머신 러닝과의 통합 증가
머신 러닝 및 딥 러닝 과 같은 AI 기술은 약물 발견 및 개발 프로세스에서 생성된 방대한 양의 데이터를 분석할 수 있습니다. HTS 데이터, 화학 및 생물학 데이터베이스, 임상 시험 데이터를 포함한 다양한 데이터 세트를 처리함으로써 AI 알고리즘은 인간 연구자에게 쉽게 드러나지 않을 수 있는 패턴, 관계 및 추세를 식별할 수 있습니다. 이를 통해 잠재적인 약물 후보의 식별을 가속화하고 약물 발견 프로세스를 최적화하는 데 도움이 될 수 있습니다.
데이터 과학과 AI는 약물 발견 및 개발에서 점점 더 중요해지고 있습니다. AI는 새로운 치료법을 생성하는 것 외에도 기존 약물 발견 및 임상 팀의 작업을 가속화하여 정보에 입각하고 매우 정확한 연구 결정을 내리는 데 도움이 됩니다.
따라서 약물 발견 및 개발에 AI를 통합하면 프로세스가 가속화되고, 성공률이 높아지고, 비용이 절감될 가능성이 있으며, 이는 시장 성장의 기회를 창출할 것으로 기대됩니다.
제약 /도전
- 세포 및 분자 샘플과 관련된 복잡성
세포 및 분자 샘플은 본질적으로 복잡하며, 여러 세포 구성 요소, 복잡한 신호 전달 경로 및 역동적인 분자 상호 작용으로 구성됩니다. 이러한 복잡성을 분석하려면 고급 이미징 기술, 특수 시약 및 정교한 알고리즘이 필요하여 데이터를 정확하게 캡처하고 해석해야 합니다. 세포 및 분자 샘플과 관련된 복잡성은 상당한 과제를 제시하며, 이는 시장 성장을 제한할 것으로 예상됩니다.
- HCS를 운영할 수 있는 숙련되고 인증된 전문가가 부족합니다.
HCS 시스템을 운영하는 데 능숙한 숙련된 전문가가 부족하면 이러한 기술의 채택과 활용이 제한될 수 있습니다. 조직은 장비를 효과적으로 운영하고 유지하는 데 필요한 인력이 없다면 HCS 플랫폼에 투자하는 것을 주저할 수 있습니다.
HCS는 복잡한 영상 시스템, 데이터 분석 소프트웨어 및 분석 최적화를 처리하는 데 전문성이 필요합니다. 경험이 부족한 운영자는 프로토콜을 최적화하는 데 어려움을 겪을 수 있으며, 이로 인해 최적이 아닌 성능과 손상된 결과가 발생할 수 있습니다. 숙련된 전문가는 HCS 분석에서 신뢰할 수 있고 고품질의 데이터를 얻는 데 필수적입니다. 따라서 HCS를 운영할 수 있는 숙련되고 인증된 전문가가 부족하면 시장 성장에 어려움이 있을 것으로 예상됩니다.
최근 개발 사항
- 2023년 1월, Axion BioSystems는 Omni 라이브 셀 이미징 제품군에 Omni Pro 12를 추가한다고 발표했습니다. 통합 로봇과 모든 표준 인큐베이터와 호환되는 여러 디자인을 특징으로 하는 이 새로운 플랫폼은 라이브 셀 이미징 실험을 수행하는 과학자와 약물 개발자에게 향상된 유연성과 효율성을 제공합니다. 이미징 기술의 이러한 발전은 라이브 셀 이미징 실험을 통해 약물 발견이 효율적으로 이루어질 수 있도록 도울 것입니다.
- 2019년 12월, 올림푸스는 차세대 생물학 연구를 가능하게 하는 인공지능(AI)을 활용한 세포 이미징 솔루션인 scanR HCS 스테이션의 미국 출시를 발표했습니다. 이 솔루션은 현미경 기반 설정의 모듈성과 유연성을 HCS 스테이션의 자동화, 속도, 처리량 및 재현성과 결합합니다. 올림푸스의 자체 학습 현미경 기술은 광표백을 줄이고 획득 속도, 측정 감도 및 정확도를 개선하여 세포 생존력에 미치는 영향을 줄이면서 더 긴 관찰을 용이하게 합니다.
유럽 고콘텐츠 스크리닝 시장 범위
유럽 고함량 스크리닝 시장은 제품 유형, 응용 프로그램, 기술, 최종 사용자 및 유통 채널을 기준으로 5개의 주요 세그먼트로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
제품 유형
- 악기
- 소모품
- 소프트웨어
- 서비스
- 부속품
제품 유형을 기준으로 시장은 계측기, 소모품, 소프트웨어, 서비스, 액세서리로 구분됩니다.
애플리케이션
- 1차 및 2차 검진
- 타겟 식별 및 검증
- 독성 연구
- 복합 프로파일링
- 기타
시장은 응용 분야를 기준으로 1차 및 2차 스크리닝, 표적 식별 및 검증, 독성 연구, 화합물 프로파일링 및 기타로 구분됩니다.
기술
- 현미경 사용
- 유세포분석
- 세포외 기질 기반 스캐폴드
- 웨스턴 블로팅
- 엘리사
- 면역조직화학
- 기타
기술은 현미경, 유세포 분석, 세포외 기질 기반 스캐폴드, 웨스턴 블로팅, ELISA, 면역조직화학 및 기타로 구분됩니다.
최종 사용자
- 제약 및 생명공학 회사
- 학술 및 정부 기관
- 계약 연구 기관
- 실험실
- 기타
최종 사용자를 기준으로 시장은 제약 및 생명공학 회사, 학계 및 정부 기관, 계약 연구 기관, 실험실 및 기타로 구분됩니다.
유통 채널
- 직접 입찰
- 소매 판매
유통 채널을 기준으로 시장은 직접 입찰과 소매 판매 로 구분됩니다 .
유럽 고콘텐츠 스크리닝 시장 지역 분석/통찰력
유럽 고함량 스크리닝 시장은 제품 유형, 응용 분야, 기술, 최종 사용자 및 유통 채널을 기준으로 5개의 주요 세그먼트로 분류됩니다.
이 시장 보고서에 포함된 국가로는 독일, 프랑스, 영국, 이탈리아, 스페인, 러시아, 터키, 벨기에, 덴마크, 네덜란드, 스위스, 스웨덴, 폴란드, 노르웨이, 핀란드, 기타 유럽 국가가 있습니다.
독일은 고품질 스크리닝에 대한 투자가 증가하고 신흥시장과 확장 수요도 늘어나면서 유럽 지역을 장악할 것으로 예상되며, 이로 인해 시장 성장이 촉진될 것으로 기대됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 유럽 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 유럽 고콘텐츠 스크리닝 시장 점유율 분석
유럽 고함량 스크리닝 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭 및 호흡, 응용 프로그램 우세, 제품 유형 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 유럽 고함량 스크리닝 시장에 대한 회사의 초점과만 관련이 있습니다.
유럽 고함량 스크리닝 시장에서 활동하는 주요 시장 참여자로는 BD, Merck KGaA, Corning Incorporated, Carl Zeiss AG, Sartorius AG, Zifo RnD Solutions, Axxam SpA, Molecular Devices, LLC. (Danaher Corporation의 자회사), Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Yokogawa Electric Corporation, Sysmex Corporation, Genedata AG, Miltenyi Biotec, Aligned Genetics, Inc. 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE HIGH CONTENT SCREENING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EUROPE HIGH CONTENT SCREENING MARKET: REGULATIONS
6 MARKET OVERVIEW, EUROPE HIGH CONTENT SCREENING MARKET
6.1 DRIVERS
6.1.1 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH CONTENT SCREENING
6.1.2 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.1.3 INCREASING RESEARCH ACTIVITIES ASSOCIATED WITH THE USAGE OF HIGH CONTENT SCREENING
6.1.4 INCREASING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH INITIAL SETUP AND MAINTENANCE
6.2.2 COMPLEXITY ASSOCIATED WITH CELLULAR AND MOLECULAR SAMPLES
6.3 OPPORTUNITIES
6.3.1 GROWING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS) PROVIDING HCS SERVICES
6.3.2 RISING INTEGRATION WITH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY AND DEVELOPMENT
6.3.3 INCREASING GOVERNMENT INITIATIVE AND FUNDING IN R&D
6.4 CHALLENGES
6.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS TO OPERATE HCS
6.4.2 DATA SECURITY AND DATA MANAGEMENT PROBLEMS IN HCS
7 EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 CELL IMAGING AND ANALYSIS SYSTEM
7.2.1.1 FIXED
7.2.1.2 MOBILE
7.2.2 HIGH-CONTENT AND SCREENING SYSTEM
7.2.2.1 FIXED
7.2.2.2 MOBILE
7.2.3 FLOW CYTOMETRY
7.2.4 INVITROGEN HCA ONSTAGE INCUBATOR
7.2.5 MICROPLATE MOVER
7.2.6 OTHERS
7.3 SOFTWARE
7.4 CONSUMABLES
7.4.1 REAGENTS & ASSAY KITS
7.4.2 MICROPLATES
7.4.3 OTHERS
7.5 ACCESSORIES
7.6 SERVICES
8 EUROPE HIGH CONTENT SCREENING MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 PRIMARY AND SECONDARY SCREENING
8.2.1 INSTRUMENTS
8.2.2 CONSUMABLES
8.2.3 ACCESSORIES
8.2.4 SERVICES
8.3 TARGET IDENTIFICATION AND VALIDATION
8.3.1 INSTRUMENTS
8.3.2 CONSUMABLES
8.3.3 ACCESSORIES
8.3.4 SERVICES
8.4 TOXICITY STUDIES
8.4.1 INSTRUMENTS
8.4.2 CONSUMABLES
8.4.3 ACCESSORIES
8.4.4 SERVICES
8.5 COMPOUND PROFILING
8.5.1 INSTRUMENTS
8.5.2 CONSUMABLES
8.5.3 ACCESSORIES
8.5.4 SERVICES
8.6 OTHER APPLICATIONS
9 EUROPE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 MICROSCOPY
9.3 FLOW CYTOMETRY
9.4 IMMUNOHISTOCHEMISTRY
9.5 MASS SPECTROMETRY
9.6 ELISA
9.7 WESTERN BLOTTING
9.8 OTHERS
9.8.1 3D CELL CULTURE MODEL
9.8.1.1 STEROIDS
9.8.1.2 ORGANOIDS
9.8.1.3 TISSUE ON A CHIP
9.8.2 EXTRACELLULAR MATRIX BASED SCAFFOLD
9.8.3 SYNTHETIC HYDROGEL AND SCAFFOLD
10 EUROPE HIGH CONTENT SCREENING MARKET, BY END USER
10.1 OVERVIEW
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.2.1 INSTRUMENTS
10.2.2 CONSUMABLES
10.2.3 ACCESSORIES
10.2.4 SERVICES
10.3 CONTRACT RESEARCH ORGANIZATIONS
10.3.1 INSTRUMENTS
10.3.2 CONSUMABLES
10.3.3 ACCESSORIES
10.3.4 SERVICES
10.4 LABORATORIES
10.4.1 INSTRUMENTS
10.4.2 CONSUMABLES
10.4.3 ACCESSORIES
10.4.4 SERVICES
10.5 ACADEMIC AND GOVERNMENT INSTITUTES
10.5.1 INSTRUMENTS
10.5.2 CONSUMABLES
10.5.3 ACCESSORIES
10.5.4 SERVICES
10.6 OTHERS
11 EUROPE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDERS
11.3 RETAIL SALES
12 EUROPE HIGH CONTENT SCREENING MARKET, BY REGION
12.1 OVERVIEW
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 RUSSIA
12.1.7 TURKEY
12.1.8 BELGIUM
12.1.9 DENMARK
12.1.10 NETHERLANDS
12.1.11 SWITZERLAND
12.1.12 SWEDEN
12.1.13 POLAND
12.1.14 NORWAY
12.1.15 FINLAND
12.1.16 REST OF EUROPE
13 EUROPE HIGH CONTENT SCREENING MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 EUROPE CONTENT SCREENING MARKET, COMPANY PROFILES
14.1 THERMO FISHER SCIENTIFIC INC. (2022)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 MOLECULAR DEVICES, LLC. (A SUBSIDIARY OF DANAHER CORPORATION)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 PERKINELMER INC. (2022)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENTS
14.4 YOKOGAWA ELECTRIC CORPORATION (2022)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 BD
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENTS
14.6 MERCK KGAA
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 AGILENT TECHNOLOGIES, INC. (2022)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ALIGNED GENETICS, INC. (2022)
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 AXXAM S.P.A.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 BIO-RAD LABORATORIES, INC. (2022)
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 CARL ZEISS AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 CORNING INCORPORATED
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 GENEDATA AG
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MILTENYI BIOTEC
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 SARTORIUS AG
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 SYSMEX CORPORATION
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENT
14.17 ZIFO RND SOLUTIONS
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
표 목록
TABLE 1 EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 EUROPE INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 EUROPE CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 EUROPE HIGH-CONTENT AND SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 EUROPE CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 EUROPE HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 7 EUROPE PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 8 EUROPE TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 EUROPE TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 EUROPE COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 EUROPE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 12 EUROPE OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 13 EUROPE 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 14 EUROPE HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 15 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 EUROPE LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 EUROPE ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 EUROPE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 20 EUROPE HIGH CONTENT SCREENING MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 21 GERMANY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 22 GERMANY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 GERMANY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 24 GERMANY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 25 GERMANY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 26 GERMANY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 27 GERMANY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 28 GERMANY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 29 GERMANY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 30 GERMANY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 31 GERMANY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 32 GERMANY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 33 GERMANY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 34 GERMANY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 35 GERMANY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 GERMANY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 37 GERMANY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 38 GERMANY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 GERMANY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 40 FRANCE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 41 FRANCE INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 42 FRANCE CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 FRANCE HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 FRANCE CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 FRANCE HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 46 FRANCE PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 47 FRANCE TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 48 FRANCE TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 FRANCE COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 FRANCE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 51 FRANCE OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 52 FRANCE 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 53 FRANCE HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 54 FRANCE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 55 FRANCE CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 FRANCE LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 57 FRANCE ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 FRANCE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 59 U.K. HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 U.K. INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 U.K. CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 U.K. HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 U.K. CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 U.K. HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 65 U.K. PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 66 U.K. TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 67 U.K. TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 68 U.K. COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 69 U.K. HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 70 U.K. OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 71 U.K. 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 72 U.K. HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 73 U.K. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 74 U.K. CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 75 U.K. LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 76 U.K. ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 U.K. HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 78 ITALY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 ITALY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 ITALY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 ITALY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 ITALY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 83 ITALY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 84 ITALY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 ITALY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 86 ITALY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 ITALY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 ITALY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 89 ITALY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 90 ITALY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 91 ITALY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 92 ITALY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 93 ITALY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 ITALY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 ITALY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 96 ITALY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 97 SPAIN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 SPAIN INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 SPAIN CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 SPAIN HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 SPAIN CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 102 SPAIN HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 103 SPAIN PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 104 SPAIN TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 105 SPAIN TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 106 SPAIN COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 SPAIN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 108 SPAIN OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 109 SPAIN 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 110 SPAIN HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 111 SPAIN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 SPAIN CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 SPAIN LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 SPAIN ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 SPAIN HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 116 RUSSIA HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 117 RUSSIA INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 RUSSIA CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 119 RUSSIA HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 RUSSIA CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 121 RUSSIA HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 122 RUSSIA PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 RUSSIA TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 RUSSIA TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 RUSSIA COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 RUSSIA HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 127 RUSSIA OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 128 RUSSIA 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 129 RUSSIA HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 130 RUSSIA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 RUSSIA CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 132 RUSSIA LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 RUSSIA ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 134 RUSSIA HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 135 TURKEY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 136 TURKEY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 137 TURKEY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 138 TURKEY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 TURKEY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 140 TURKEY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 141 TURKEY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 TURKEY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 143 TURKEY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 TURKEY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 TURKEY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 146 TURKEY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 147 TURKEY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 148 TURKEY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 149 TURKEY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 TURKEY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 TURKEY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 152 TURKEY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 153 TURKEY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 154 BELGIUM HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 BELGIUM INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 BELGIUM CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 BELGIUM HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 158 BELGIUM CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 159 BELGIUM HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 160 BELGIUM PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 BELGIUM TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 162 BELGIUM TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 BELGIUM COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 164 BELGIUM HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 165 BELGIUM OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 166 BELGIUM 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 167 BELGIUM HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 168 BELGIUM PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 169 BELGIUM CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 170 BELGIUM LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 171 BELGIUM ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 BELGIUM HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 173 DENMARK HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 174 DENMARK INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 175 DENMARK CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 DENMARK HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 DENMARK CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 DENMARK HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 179 DENMARK PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 DENMARK TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 181 DENMARK TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 182 DENMARK COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 183 DENMARK HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 184 DENMARK OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 185 DENMARK 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 186 DENMARK HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 187 DENMARK PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 188 DENMARK CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 189 DENMARK LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 DENMARK ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 191 DENMARK HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 192 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 NETHERLANDS INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 194 NETHERLANDS CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 195 NETHERLANDS HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 196 NETHERLANDS CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 198 NETHERLANDS PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 199 NETHERLANDS TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 200 NETHERLANDS TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 201 NETHERLANDS COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 202 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 203 NETHERLANDS OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 204 NETHERLANDS 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 205 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 206 NETHERLANDS PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 207 NETHERLANDS CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 208 NETHERLANDS LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 209 NETHERLANDS ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 210 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 211 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 SWITZERLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 SWITZERLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 SWITZERLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 SWITZERLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 217 SWITZERLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 218 SWITZERLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 219 SWITZERLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 SWITZERLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 221 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 222 SWITZERLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 223 SWITZERLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 224 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 225 SWITZERLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 SWITZERLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 227 SWITZERLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 228 SWITZERLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 229 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 230 SWEDEN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 SWEDEN INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 232 SWEDEN CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 233 SWEDEN HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 234 SWEDEN CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 235 SWEDEN HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 236 SWEDEN PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 237 SWEDEN TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 238 SWEDEN TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 239 SWEDEN COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 240 SWEDEN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 241 SWEDEN OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 242 SWEDEN 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 243 SWEDEN HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 244 SWEDEN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 SWEDEN CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 SWEDEN LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 SWEDEN ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 248 SWEDEN HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 249 POLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 POLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 251 POLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 252 POLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 POLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 254 POLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 255 POLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 256 POLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 257 POLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 258 POLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 259 POLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 260 POLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 261 POLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 262 POLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 263 POLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 264 POLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 265 POLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 266 POLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 267 POLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 268 NORWAY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 269 NORWAY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 270 NORWAY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 271 NORWAY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 272 NORWAY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 273 NORWAY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 274 NORWAY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 NORWAY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 276 NORWAY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 NORWAY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 NORWAY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 279 NORWAY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 280 NORWAY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 281 NORWAY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 282 NORWAY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 NORWAY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 284 NORWAY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 285 NORWAY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 286 NORWAY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 287 FINLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 288 FINLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 289 FINLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 290 FINLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 291 FINLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 292 FINLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 293 FINLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 294 FINLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 295 FINLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 FINLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 297 FINLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 298 FINLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 299 FINLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 300 FINLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 301 FINLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 302 FINLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 303 FINLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 304 FINLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 305 FINLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 306 REST OF EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
그림 목록
FIGURE 1 EUROPE HIGH CONTENT SCREENING MARKET: SEGMENTATION
FIGURE 2 EUROPE HIGH CONTENT SCREENING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE HIGH CONTENT SCREENING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HIGH CONTENT SCREENING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HIGH CONTENT SCREENING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HIGH CONTENT SCREENING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HIGH CONTENT SCREENING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE HIGH CONTENT SCREENING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE HIGH CONTENT SCREENING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HIGH CONTENT SCREENING MARKET: SEGMENTATION
FIGURE 11 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH-CONTENT SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE HIGH CONTENT SCREENING MARKET IN THE FORECAST PERIOD
FIGURE 12 THE PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HIGH CONTENT SCREENING MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE HIGH CONTENT SCREENING MARKET
FIGURE 14 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, 2022
FIGURE 19 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 20 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 21 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 22 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, 2022
FIGURE 23 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, 2023-2030 (USD THOUSAND)
FIGURE 24 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 25 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, 2022
FIGURE 27 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 28 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 32 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 EUROPE HIGH CONTENT SCREENING MARKET: SNAPSHOT (2022)
FIGURE 35 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2022)
FIGURE 36 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 39 EUROPE HIGH CONTENT SCREENING MARKET: COMPANY SHARE 2022 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
